Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Picotamide→

Picotamide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
32828-81-2
Molecular formula
C21H20N4O3
Molecular weight
376.41 g/mol
Drug class
Antiplatelet agentthromboxane A2 receptor antagonist and thromboxane synthase inhibitor
Mechanism of action
Inhibits platelet aggregation through antagonism of thromboxane A2 receptors and inhibition of thromboxane A2 synthesis. Clinical pharmacology studies show reduced platelet aggregation and thromboxane-related activity, although the relative contribution of the two actions varies by experimental setting.
Indications / reported uses
  • Historically used for peripheral arterial disease and thrombotic vascular disorders in selected countries; current availability and authorisation are jurisdiction-specific.

Sources: https://pubmed.ncbi.nlm.nih.gov/2048055/ · https://pubmed.ncbi.nlm.nih.gov/8032666/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Picotamide Environmental Risk Assessment (ERA) (the Picotamide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.